NEW YORK – Finnish medical device manufacturer ArcDia International said on Monday that its automated SARS-CoV-2 antigen point-of-care test has received CE marking and is commercially available.
The test runs on the MariPOC automated platform and is available as part of a multianalyte respiratory panel identifying 11 pathogens and as a single-target test for high-capacity rapid testing. The rapid test detects the virus from a swab sample, and up to 300 samples a day can be analyzed with one benchtop instrument. In addition, the test results are automatically transferred to the company's MariCloud service, the firm said.
ArcDia, based in Turku, said it has started delivering the test to customers and is now looking for international distribution partners, as well as a strategic partner for US commercialization.